 ATLANTA, Oct. 19, 2021 PRNewswire -- Inhibikase Therapeutics, Inc. Nasdaq: IKT Inhibikase, a clinical-stage pharmaceutical company developing therapeutics to modify the course of Parkinsons disease and related disorders, today announced dosing of the first Parkinsons patient in its Phase 1b clinical trial of IkT-148009, an Abelson Tyrosine Kinase, or c-Abl, inhibitor for the treatment of Parkinsons disease. The Phase 1b extension study is a 3:1 randomized, placebo-controlled trial investigating the safety, tolerability and pharmacokinetics of IkT-148009. 